Keyphrases
Effector Proteins
100%
Anticancer Activity
100%
Lung Adenocarcinoma
100%
Ras Effectors
100%
RASSF5
100%
NORE1A
100%
Cancer Development
33%
High Affinity
33%
RAS Oncogene
33%
Small Molecules
16%
Phosphorylation
16%
Tumor Suppressor Gene
16%
Therapeutic Strategies
16%
Binding Protein
16%
Cell Viability
16%
Mutant Protein
16%
Cell Cycle Progression
16%
Cell Division
16%
Acetylation
16%
Master Regulator
16%
Drug Design
16%
Computational Design
16%
Amino Acid Position
16%
Cell Apoptosis
16%
In Vitro Evolution
16%
Anticancer
16%
KRAS mutation
16%
Cellular Senescence
16%
Effectors Interaction
16%
Lung Carcinoma Cells
16%
Oncogenic Ras
16%
Activity Inhibition
16%
Constitutive Behavior
16%
Ras Small GTPases
16%
A549 Lung Carcinoma
16%
Cell Mobility
16%
Constitutive Signaling
16%
Anticancer Pathways
16%
Biochemistry, Genetics and Molecular Biology
Anticancer
100%
Antineoplastic Activity
100%
Oncogene Ras
100%
Amino Acids
50%
Guanosine Triphosphate
50%
Cell Motility
50%
P53
50%
Enzymatic Hydrolysis
50%
Tumor Suppressor Gene
50%
Binding Protein
50%
Small GTPase
50%
Cell Viability
50%
Mutant Protein
50%
Cell Cycle Progression
50%
Cell Division
50%
Acetylation
50%
Small Molecule
50%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Lung Adenocarcinoma
100%
Guanosine Triphosphate
50%
Amino Acid
50%
Protein P53
50%
Drug Development
50%
Cell Viability
50%
Lung Carcinoma
50%
Binding Protein
50%
Tumor Suppressor Protein
50%
Ras Protein
50%
Mutant Protein
50%